Clinical trials: Post-transplant Hepatitis C
Hepatitis C, Transplantation Disease Transmission
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV.
- Trial name
- PRO-ACT: (NCT03619837)
- Testing
- Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- University of California, San Francisco
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health